NCT05962502View on ClinicalTrials.gov

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 24, 2023

Primary Completion Date

March 30, 2025

Study Completion Date

December 30, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Cetuximab and irinotecan

chemotherapy plus targeted therapy

Trial Locations (1)

510060

RECRUITING

Cancer center of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER